MORINAGA-MILK-INDUSTRY
8.8.2024 20:01:28 CEST | Business Wire | Press release
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced its proprietary probiotic Bifidobacterium infantis M-63 was approved by the National Health Commission (NHC) of the People’s Republic of China as a new food ingredient for use in infant and children foods (under the age of three) on 25 July, 2024. This approval marks a significant milestone for the company, making it the only Japanese firm to have three bifidobacteria strains registered for use in China’s infant and toddler food market1.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240808893280/en/
Bifidobacterium infantis M-63 is a unique probiotic strain of human-residential bifidobacteria (HRB) – bifidobacteria that naturally reside in the human gut – and is renowned for its ability to utilize human milk oligosaccharides (HMO) found in breast milk, significantly improving the intestinal environment of healthy full-term infants. (Graphic: Business Wire)
*1 Source: Public announcement published on the website of the China National Center for Food Safety Risk Assessment (August 5, 2024)
The newly registered Bifidobacterium infantis M-63 joins Morinaga Milk’s other approved strains, Bifidobacterium breve M-16V and Bifidobacterium longum BB536. All three strains are now permitted for use in foods for children under three years old in China, meeting the country's stringent nutritional and safety standards.
Expanding Global Presence
This approval aligns with Morinaga Milk’s 10-year vision to become a globally recognized company with a significant international presence. As part of this vision, the company aims to achieve a Global Business sales ratio of 15% or more by the fiscal year ending in March 2029. The approval of Bifidobacterium infantis M-63 represents a strategic step towards this goal, allowing Morinaga Milk to strengthen its bacteria business in the Chinese market, which accounts for more than 40% of the global formula milk market and is the second-largest supplement market worldwide2.
*2 Source: Survey by Euromonitor International (May 2024), based on retail sales prices
Health Benefits of Bifidobacterium infantis M-63
Bifidobacterium infantis M-63 is a unique probiotic strain of human-residential bifidobacteria (HRB) – bifidobacteria that naturally reside in the human gut – and is renowned for its ability to utilize human milk oligosaccharides (HMO) found in breast milk, significantly improving the intestinal environment of healthy full-term infants. With China's recent approval of HMO use in formula milk in October 20233, the combination of Bifidobacterium infantis M-63 and HMO is expected to support the growth of beneficial intestinal bacteria, enhancing the development and health of infants and toddlers4.
*3 Source: National Health Commission of the People’s Republic of China, No. 8, 2023 (Sept. 22, 2023)
*4 Source: Mintel, “HMOs approval in China infant formula is a game changer” (Jan. 2024)
Probiotics strain of bifidobacteria registered as New Food Ingredients in China |
|
Strain |
Registration date |
Bifidobacterium breve M-16V Registered name: 短双歧杆菌 M-16V |
2016 |
Bifidobacterium longum subsp. longum BB536 Registered name: 长双歧杆菌长亚种 BB536 |
2022 |
Bifidobacterium longum subsp. infantis M-63 Registered name: 长双歧杆菌婴儿亚种M-63 |
2024 |
* All three strains are approved for use in foods for infants and toddlers under the age of three. |
|
Commitment to Quality and Research
Morinaga Milk has been at the forefront of bifidobacteria research since discovering Bifidobacterium longum BB536 in 1969. The company leads globally in the number of clinical research papers on bifidobacteria, underlining its commitment to advancing scientific understanding and improving public health.
Future Prospects
The registration of Bifidobacterium infantis M-63 paves the way for its use in a wide range of products. Morinaga Milk plans to leverage this approval to expand collaborations with major formula milk manufacturers and promote supplements and other related products in China and globally. By providing accurate information on the benefits of Bifidobacterium infantis M-63 to consumers and partners, Morinaga Milk aims to enhance the health and nutrition of people worldwide.
About Morinaga Milk Industry
Morinaga Milk Industry Co., Ltd. is one of the leading dairy product companies in Japan, with over a century of history in harnessing the nutritional properties of dairy products and functional ingredients. Morinaga Milk is also a key global probiotics manufacturer that excels in innovative technology and offers a premium line of probiotics and functional ingredients worldwide. Since the 1960s, Morinaga Milk has been engaged in research on the safety, functional health benefits, and mechanisms of action of probiotic bifidobacteria to better understand their role in maintaining human health. For more information about Morinaga Human-Residential Bifidobacteria (HRB) probiotics, please visit us at https://morinagamilk-ingredients.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240808893280/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom